Heritage Cannabis Announces the Upcoming Launch of CBD Product Applications Utilizing the Patented VESIsorb® Delivery System Technology in the United States, Including ArthroCBD and Topical CBD Products
Heritage Cannabis Holdings Corp. (CSE: CANN, OTCQX: HERTF) is launching new medical products in the U.S. using its patented VESIsorb® delivery system. The first product, ArthroCBD softgel capsules, containing 25 mg CBD, is set to release by April 19, 2021. Topical applications targeting health issues like eczema and pain are also nearing launch. The company will present at the NACDS annual meeting to secure retail listings. VESIsorb® technology enhances the bioavailability of cannabinoids, showing significant absorption improvements in studies.
- Launch of ArthroCBD softgel capsules with optimized absorption set for April 19, 2021.
- Use of VESIsorb® technology associated with substantial bioavailability improvements.
- Topical cannabinoid applications targeting eczema, psoriasis, and local pain in final stages of development.
- Company aims to expand into the U.S. healthcare market with innovative product offerings.
- None.
Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that, through a phased approach in 2021, the Company will be launching several new medical products formulated with the patented VESIsorb® delivery system technology in the U.S. through its subsidiary Opticann, including ArthroCBD softgel capsules as well as topical cannabinoid applications that have been formulated to address some of the most pressing consumer health concerns, such as eczema, psoriasis, and local pain.
The first product, launching by April 19, 2021 on eCommerce channels is ArthroCBD, a 25 mg CBD and 6 mg beta-caryophyllene (BCP) softgel capsule formulated with VESIsorb® for optimized absorption, bioavailability, and rapid onset of action. In addition, CBD topical applications formulated with VESIsorb® for optimized dermal penetration and permeation are in the final stages of product development with a planned launch in the summer on opticann.com as well as at leading retailers in the food, drug, and mass channel of distribution. Opticann’s CBD/CBDA sublingual filmstrip which is already planned for launch in Canada and Australia, will also be launched through the eCommerce effort later this year.
To support this effort, Opticann will present its products and brands at the National Association of Chain Drug Stores (“NACDS”) annual meeting in late April, with the expectation to be listed for launch at major U.S. retailers.
“We continue to innovate and expand our clinically proven cannabinoid product offerings as we launch our initial suite of products formulated with the VESIsorb® drug delivery system technology,” commented Umar Syed, Heritage’s President, Medical Division. “With our products, we aim to reach the broader healthcare market that includes sophisticated consumers and healthcare professionals who are seeking highly effective products that have substantial safety and efficacy data to support their utility for medical applications.”
VESIsorb® is a leading, innovative delivery system technology for dramatically improving the stability, absorption, and bioavailability of natural ingredients like cannabinoids, and is backed by a robust body of supporting scientific evidence spanning several decades. Most recently, the peer reviewed journal, Molecules, published the results of a double-blind, cross-over study (Molecules 2019,24(16), 2967) comparing the pharmacokinetic performance of a CBD extract formulated with VESIsorb® to that of the same CBD extract formulated with industry standard (MCT) oil. Overall, the VESIsorb® formulation showed statistically significant improvements for all measured parameters, including much higher total absorption (a
About Heritage Cannabis Holdings Corp.
Heritage is a cannabinoid company focused on the production and sale of medical and recreational hemp-based and cannabis-based products and services. In Canada, Heritage operates through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp., both regulated under the Cannabis Act Regulations. Working under these subsidiaries and the Purefarma, Pura Vida, Premium 5, RAD and feelgood. brands, Heritage focuses on extraction and the creation of derivative products for recreational consumers, as well as the formulation of cannabis based medical solutions. In the U.S., Heritage operates under Opticann Inc., a Colorado based oral and topical cannabinoid company with the rights to exclusively sell CBD and CBG products made with the patented VESIsorb® drug delivery system for optimized absorption and stability. As the parent company, Heritage is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.
ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.
“Clint Sharples”
Clint Sharples
CEO
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005271/en/
FAQ
What new products is Heritage Cannabis launching in 2021?
What is the launch date for ArthroCBD softgel capsules?
Which technology is used in Heritage Cannabis's new products?
How does VESIsorb® improve cannabinoid absorption?
When will topical cannabinoid applications be launched?
